← All trials
NCT03092544
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2015
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- MS Center of Northeastern New YorkLead sponsor
- MS Center of Northeastern New YorkOverall official - principal investigator
- BiogenCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.